This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Asthma; allergy	Oxoeicosanoid receptor 1 (OXER1; GPR170)	<p><i>In vitro</i> studies identified OXER1 antagonists that could help treat asthma and allergic diseases. Compounds that incorporated an indole scaffold and structural components of 5-oxo-eicosatetraenoic acid (ETE) antagonized OXER1 with IC₅₀ values of about 30 nM. In cell culture, pretreatment with either of the two most potent compounds inhibited actin polymerization and chemotaxis of neutrophils and eosinophils induced by 5-oxo-ETE. Next steps include testing the antagonists in animal models of asthma or other allergic diseases.</p> <p>SciBX 7(3); doi:10.1038/scibx.2014.91 Published online Jan. 23, 2014</p>	Patent application filed covering antagonists; licensed by AmorChem Holdings Inc.; available for licensing	<p>Gore, V. <i>et al. J. Med. Chem.</i>; published online Dec. 18, 2013; doi:10.1021/jm401292m Contact: William S. Powell, McGill University, Montreal, Quebec, Canada e-mail: william.powell@mcgill.ca Contact: Pranav Patel, Navinta LLC, Ewing, N.J. e-mail: pranav.patel@navinta.com Contact: Vivek Gore, same affiliation as above e-mail: vivek.gore@navinta.com</p>